GSK Annual Report 2002

160 GlaxoSmithKline Index
O
Oncology and emesis 7-9,16,21,55,56,67-69,82,
144-148
Operating and financial review
and prospects 51-72
Oral care 6,9,13,14,22,57,69,86,148
Other operating income/(expense) 57,58,69,70,
76,89,126,142
Outlook 53,64
Over-the-counter (OTC) medicines 6,9,11,13,57,69
82,86,148
P
Patents 3,4,10-13,23,54,64,65,84,95,103-107,130
Payment policies 62
Pension and other post-retirement
benefits 43-45,50,59,60,72,78,84,92,97,98,
114-118,123,126,128-133,136,137
Pharmaceuticals
approvals and submissions 11,12,19
business sector 6,86-88,132,134,135,148
competition 10
manufacturing and supply 13,14
marketing and distribution 13
products 7-14,19,53,54,58,64
sales 8,10,13,37,52-56,64-69,86,
142-148
research and development 10,14-22,25,37,52,
57,58,62,69,76,82,83,114,126,130,136,
142,150
regulation 11-12
patents and trade marks 5,23
Pipeline 14-17
Presentation of financial statements 82
Price controls 12,64
Profit and loss account 2,52,57,59,69,71,76-77,
80-85,92,102,113,117,118,122,123,142,149
Property, plant and equipment 25,125
Provisions for liabilities and charges 60,61,80,90
R
Reconciliation of equity of movements
in equity shareholders’ funds 80,82
Registrar 153
Regulation 11,12
Remuneration Committee 34,40
Remuneration report 39-50
Report of the Directors 2-72
Research collaborations 21,110
Research and development
accounting policy 83
animals and research 22
Consumer Healthcare 22
diseases of the developing world 21,27
expenditure 52,57,58,69,76,126,142
Pharmaceuticals 14-22
pipeline 14-17
Respiratory 7-10,15,17,20-22,53-57,66,67,82,
144-148
Return on capital employed 149
Revenue – accounting policy 83
Risk factors 64,65
Risk Oversight and Compliance Council (ROCC) 36
page page page
S
Sales
Consumer Healthcare 52,57,69,86,134,135,
142,148
Pharmaceuticals 8,10,13,37,52-56,64-66,68,
69,86,142-148
SB Clinical laboratories 107,108
Segment information 6,86-88,132,134,135,
139-141,148
Selected financial data 71
Senior management – compensation
and interests 50
Share buy-back 35,58,59,62,82,101,102
Share capital 35,50,79-81,101,125,128,150,154
Share premium 80,81,85,101,150
Share price 46,48,49,53,152-154
Share purchases 62,63
Share statistics 149
Shareholder information 153
Shareholder return 42,119,120,152
Shareholders’ funds 60,80,82
Shareholdings – analysis 155
Statement of total
recognised gains and losses 76,77
T
Taxation 58-61,70,76,78,81,83,85-89,91,92,97,
98,124,126,129,130,133,134,142
Taxation information for shareholders 156
Tax rate 52,58,65,70,85,91,130
Trade marks 5,23
Treasury operations 37,62,85
Treasury policies 62,63
Tuberculosis 27
U
UK segment 88
US GAAP – reconciliation to US accounting
principles 122-138
consolidated balance sheet 125
consolidated income statement 126,127
comprehensive income and
changes in shareholders’ equity 126,127
consolidated statement of cash flows 124,128
earnings per share/ADS 133
material differences between
UK and US GAAP 122-124
post-retirement benefits 123,136-138
purchase accounting 130,131
results under US accounting principles 72
segment information 134,135
selected financial data 71
taxation 133
V
Vaccines 6-8,10,11,14,17,21,22,27,54-56,67-69
82,86,105,144-148
W
World economy 53
World market 53